董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Garry A. Nicholson Director 61 94.21万(USD) -- 2016-04-01
Kavita Patel. Director 42 -- -- 2016-04-01
Mary Lynne Hedley Director,Chief Executive Officer 53 459.86万(USD) -- 2016-04-01
James O. Armitage Director 69 39.56万(USD) -- 2016-04-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jeffrey H. Hanke Executive Vice President, Research and Development, and Chief Scientific Officer 59 648.34万(USD) -- 2016-04-01
Grant C. Bogle Senior Vice President and Chief Commercial Officer 58 304.48万(USD) -- 2016-04-01
Martin H. Huber Senior Vice President and Chief Medical Officer 56 -- -- 2016-04-01
Joseph L. Farmer Senior Vice President, General Counsel and Secretary 44 -- -- 2016-04-01
Mary Lynne Hedley Director,Chief Executive Officer 53 459.86万(USD) -- 2016-04-01

董事简历

中英对照 |  中文 |  英文
Garry A. Nicholson

Garry A. Nicholson,他担任我们的董事(2015年5月以来)。他曾一直担任XTuit Pharmaceuticals, Inc.(生物制药公司)的总裁、首席执行官兼董事会成员(2015年9月以来)。此前,他曾担任Pfizer Oncology公司的总裁(从2008年5月到2015年3月)。他曾加入Pfizer, Inc.,担任其全球第一领导人,致力于肿瘤学的生意,并直接负责业务战略和运营。他曾负责早期和晚期阶段的药物临床开发、所有肿瘤全球销售和营销机构、许可、收购和肿瘤学的治疗领域策略。除了担任肿瘤职务,他曾担任投资策略和投资委员会(管理主体,负责监督Pfizer研发)的成员。他曾一直担任Pfizer Foundation的董事会成员。加入Pfizer公司之前,他曾任职Eli Lilly and Company ("Lilly"),担任多种领导职务,包括销售管理、市场营销、人力资源,也是意大利医药商业领袖。他曾于1996年开始负责Lilly公司的癌症产品在美国的销售和市场营销,随后负责肿瘤药物的研发管理。他持有北卡罗莱纳大学教堂山分校(the University of North Carolina, Chapel Hill)的药学学士学位,以及哥伦比亚南卡罗来纳大学(University of South Carolina)的工商管理硕士学位。他也曾任职于SQZ Biotech公司(细胞疗法公司)的董事会(2015年12月以来)。


Garry A. Nicholson has served on our board of directors since May 2015. Mr. Nicholson has served as President, Chief Executive Officer and a member of the board of directors of XTuit Pharmaceuticals, Inc., a biopharmaceutical company, since September 2015. Prior to that, he served as President, Pfizer Oncology, from May 2008 until March 2015. He joined Pfizer, Inc. "Pfizer", as the first leader of its global, dedicated oncology business, with direct responsibility for business strategy and operations. He was responsible for clinical development for both early and late stage medicines, for all oncology sales and marketing organizations globally, and for licensing, acquisitions, and the oncology therapeutic area strategy. In addition to his oncology role, he was a member of the Portfolio Strategy and Investment Committee, the governance body with the oversight responsibility for Pfizer research and development. He also served as a member of the Pfizer Foundation board of directors. Prior to joining Pfizer, Mr. Nicholson worked at Eli Lilly and Company ("Lilly"), in a number of leadership roles, including sales management, marketing, human resources, and as the pharmaceutical commercial leader in Italy. He assumed the responsibility for the sales and marketing of Lilly's cancer products in the U.S. in 1996 and subsequently managed oncology drug development. Mr. Nicholson earned a bachelor of science degree in pharmacy from the University of North Carolina, Chapel Hill, and a master of business administration degree from the University of South Carolina, Columbia. Mr. Nicholson has also served on the board of directors of SQZ Biotech, a cell therapy company, since December 2015.
Garry A. Nicholson,他担任我们的董事(2015年5月以来)。他曾一直担任XTuit Pharmaceuticals, Inc.(生物制药公司)的总裁、首席执行官兼董事会成员(2015年9月以来)。此前,他曾担任Pfizer Oncology公司的总裁(从2008年5月到2015年3月)。他曾加入Pfizer, Inc.,担任其全球第一领导人,致力于肿瘤学的生意,并直接负责业务战略和运营。他曾负责早期和晚期阶段的药物临床开发、所有肿瘤全球销售和营销机构、许可、收购和肿瘤学的治疗领域策略。除了担任肿瘤职务,他曾担任投资策略和投资委员会(管理主体,负责监督Pfizer研发)的成员。他曾一直担任Pfizer Foundation的董事会成员。加入Pfizer公司之前,他曾任职Eli Lilly and Company ("Lilly"),担任多种领导职务,包括销售管理、市场营销、人力资源,也是意大利医药商业领袖。他曾于1996年开始负责Lilly公司的癌症产品在美国的销售和市场营销,随后负责肿瘤药物的研发管理。他持有北卡罗莱纳大学教堂山分校(the University of North Carolina, Chapel Hill)的药学学士学位,以及哥伦比亚南卡罗来纳大学(University of South Carolina)的工商管理硕士学位。他也曾任职于SQZ Biotech公司(细胞疗法公司)的董事会(2015年12月以来)。
Garry A. Nicholson has served on our board of directors since May 2015. Mr. Nicholson has served as President, Chief Executive Officer and a member of the board of directors of XTuit Pharmaceuticals, Inc., a biopharmaceutical company, since September 2015. Prior to that, he served as President, Pfizer Oncology, from May 2008 until March 2015. He joined Pfizer, Inc. "Pfizer", as the first leader of its global, dedicated oncology business, with direct responsibility for business strategy and operations. He was responsible for clinical development for both early and late stage medicines, for all oncology sales and marketing organizations globally, and for licensing, acquisitions, and the oncology therapeutic area strategy. In addition to his oncology role, he was a member of the Portfolio Strategy and Investment Committee, the governance body with the oversight responsibility for Pfizer research and development. He also served as a member of the Pfizer Foundation board of directors. Prior to joining Pfizer, Mr. Nicholson worked at Eli Lilly and Company ("Lilly"), in a number of leadership roles, including sales management, marketing, human resources, and as the pharmaceutical commercial leader in Italy. He assumed the responsibility for the sales and marketing of Lilly's cancer products in the U.S. in 1996 and subsequently managed oncology drug development. Mr. Nicholson earned a bachelor of science degree in pharmacy from the University of North Carolina, Chapel Hill, and a master of business administration degree from the University of South Carolina, Columbia. Mr. Nicholson has also served on the board of directors of SQZ Biotech, a cell therapy company, since December 2015.
Kavita Patel.

Kavita Patel.,2016年3月以来,她担任我们的董事会职务。2011年1月以来,她担任The Brookings Institution(主要研究和思想领导组织)的非居民高级研究员。担任该职位时,她为 the Department of Economic Studies of the Institution的the Center for Health Policy高级视觉和指导,特别帮助医疗系统理解如何改变他们的临床环境,使他们所提供的护理成为更有责任感。2011年1月以来,她在Johns Hopkins进行初级保健医生实践。从2009年到2010年,她担任The White House的政府间事务和公众参与办公室的政策主管。此前从2007年到2009年,她担任Senator Edward M. Kennedy的员工的健康副主管。她目前担任SSM Healthcare(非营利性综合交付系统)、Community Catalyst(一个国家倡导组织)和the National Initiative for Children's Healthcare Quality的董事会成员。她也是the National Commission on Physician Payment Reform、the Robert Graham Center for Policy Studies in Family Medicine and Primary Care和the Johns Hopkins Medicine Sibley Hospital Innovation Hub的咨询委员会成员。她获得奥斯汀the University of Texas的学士学位、the University of Texas Health Science Center的医学博士和洛杉矶the University of California的硕士学位(M.S.H.S.)。


Kavita Patel. has served on our board of directors since March 2016. Dr. Patel has been a Non Resident Senior Fellow at The Brookings Institution, a premier research and thought leadership organization, since January 2011. In this role, Dr. Patel provides senior level vision and guidance for the Center for Health Policy in the Department of Economic Studies of the Institution, specifically helping healthcare systems understand how to transform their clinical environments to become more accountable for the care they provide. Dr. Patel has also been a practicing primary care physician at Johns Hopkins since January 2011. From 2009 to 2010 she served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House. Prior to that, she served as Deputy Staff Director for Health for Senator Edward M. Kennedy from 2007 to 2009. Dr. Patel currently serves as a member of the Board of Directors of SSM Healthcare, a nonprofit integrated delivery system, Community Catalyst, a national advocacy organization, and the National Initiative for Children's Healthcare Quality. She is also a member of the advisory board for the National Commission on Physician Payment Reform, the Robert Graham Center for Policy Studies in Family Medicine and Primary Care, and the Johns Hopkins Medicine Sibley Hospital Innovation Hub. Dr. Patel earned her B.A. from the University of Texas at Austin, her M.D. from the University of Texas Health Science Center, and her M.S.H.S. from the University of California, Los Angeles.
Kavita Patel.,2016年3月以来,她担任我们的董事会职务。2011年1月以来,她担任The Brookings Institution(主要研究和思想领导组织)的非居民高级研究员。担任该职位时,她为 the Department of Economic Studies of the Institution的the Center for Health Policy高级视觉和指导,特别帮助医疗系统理解如何改变他们的临床环境,使他们所提供的护理成为更有责任感。2011年1月以来,她在Johns Hopkins进行初级保健医生实践。从2009年到2010年,她担任The White House的政府间事务和公众参与办公室的政策主管。此前从2007年到2009年,她担任Senator Edward M. Kennedy的员工的健康副主管。她目前担任SSM Healthcare(非营利性综合交付系统)、Community Catalyst(一个国家倡导组织)和the National Initiative for Children's Healthcare Quality的董事会成员。她也是the National Commission on Physician Payment Reform、the Robert Graham Center for Policy Studies in Family Medicine and Primary Care和the Johns Hopkins Medicine Sibley Hospital Innovation Hub的咨询委员会成员。她获得奥斯汀the University of Texas的学士学位、the University of Texas Health Science Center的医学博士和洛杉矶the University of California的硕士学位(M.S.H.S.)。
Kavita Patel. has served on our board of directors since March 2016. Dr. Patel has been a Non Resident Senior Fellow at The Brookings Institution, a premier research and thought leadership organization, since January 2011. In this role, Dr. Patel provides senior level vision and guidance for the Center for Health Policy in the Department of Economic Studies of the Institution, specifically helping healthcare systems understand how to transform their clinical environments to become more accountable for the care they provide. Dr. Patel has also been a practicing primary care physician at Johns Hopkins since January 2011. From 2009 to 2010 she served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House. Prior to that, she served as Deputy Staff Director for Health for Senator Edward M. Kennedy from 2007 to 2009. Dr. Patel currently serves as a member of the Board of Directors of SSM Healthcare, a nonprofit integrated delivery system, Community Catalyst, a national advocacy organization, and the National Initiative for Children's Healthcare Quality. She is also a member of the advisory board for the National Commission on Physician Payment Reform, the Robert Graham Center for Policy Studies in Family Medicine and Primary Care, and the Johns Hopkins Medicine Sibley Hospital Innovation Hub. Dr. Patel earned her B.A. from the University of Texas at Austin, her M.D. from the University of Texas Health Science Center, and her M.S.H.S. from the University of California, Los Angeles.
Mary Lynne Hedley

Mary Lynne Hedley自2010年3月共同创办公司担任公司总裁兼首席科学官,并是我们的董事会成员,从2009年7月至2010年2月Hedley博士担任Abraxis生物科学公司的运营部执行副总裁兼首席科学官,这是一家生物技术公司。从2008年1月至2009年7月Hedley博士担任北美卫材公司(Eisai Corporation of North America)的执行副总裁,该公司于2008年1月被MGI PHARMA公司收购。Hedley博士从2004年到2008年1月它收购Eisai,曾在MGI PHARMA不同的岗位任职,最近担任执行副总裁兼首席科学官。在此之前,Hedley博士于2004年共同创办Zycos,博士担任ZYCOS公司的总裁兼首席执行官,是一家生物技术公司,该公司被MGI制药公司收购。Hedley获得哈佛大学(Harvard University)两个连续的博士后奖学金。Hedley博士获得普渡大学(Purdue University)微生物学士学位和德克萨斯大学西南医学中心(the University of Texas, Southwestern Medical Center)免疫博士学位。


Mary Lynne Hedley has served as our President and as a member of our board of directors since co-founding the Company in March 2010. She also served in the role of Chief Scientific Officer from the Company's founding until the board of directors appointed her to the role of Chief Operating Officer effective July 24 2014. From July 2009 to February 2010 Dr. Hedley served as executive vice president of operations and chief scientific officer of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley served as executive vice president of Eisai Corporation of North America from January 2008 until July 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc. in January 2008. Dr. Hedley served in various positions at MGI PHARMA, Inc. from 2004 through its acquisition in January 2008 most recently as executive vice president and chief scientific officer. Prior to that, Dr. Hedley co-founded and served as the president and chief executive officer of ZYCOS, Inc., a biotechnology company, which was acquired by MGI PHARMA, Inc. in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University. Dr. Hedley earned a bachelor of science degree in microbiology from Purdue University and degree in immunology from the University of Texas, Southwestern Medical Center. Dr. Hedley currently serves as a director of Youville Place, Inc. She also served on the board of Receptos, Inc. prior to its acquisition by Celgene Corp. in August 2015.
Mary Lynne Hedley自2010年3月共同创办公司担任公司总裁兼首席科学官,并是我们的董事会成员,从2009年7月至2010年2月Hedley博士担任Abraxis生物科学公司的运营部执行副总裁兼首席科学官,这是一家生物技术公司。从2008年1月至2009年7月Hedley博士担任北美卫材公司(Eisai Corporation of North America)的执行副总裁,该公司于2008年1月被MGI PHARMA公司收购。Hedley博士从2004年到2008年1月它收购Eisai,曾在MGI PHARMA不同的岗位任职,最近担任执行副总裁兼首席科学官。在此之前,Hedley博士于2004年共同创办Zycos,博士担任ZYCOS公司的总裁兼首席执行官,是一家生物技术公司,该公司被MGI制药公司收购。Hedley获得哈佛大学(Harvard University)两个连续的博士后奖学金。Hedley博士获得普渡大学(Purdue University)微生物学士学位和德克萨斯大学西南医学中心(the University of Texas, Southwestern Medical Center)免疫博士学位。
Mary Lynne Hedley has served as our President and as a member of our board of directors since co-founding the Company in March 2010. She also served in the role of Chief Scientific Officer from the Company's founding until the board of directors appointed her to the role of Chief Operating Officer effective July 24 2014. From July 2009 to February 2010 Dr. Hedley served as executive vice president of operations and chief scientific officer of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley served as executive vice president of Eisai Corporation of North America from January 2008 until July 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc. in January 2008. Dr. Hedley served in various positions at MGI PHARMA, Inc. from 2004 through its acquisition in January 2008 most recently as executive vice president and chief scientific officer. Prior to that, Dr. Hedley co-founded and served as the president and chief executive officer of ZYCOS, Inc., a biotechnology company, which was acquired by MGI PHARMA, Inc. in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University. Dr. Hedley earned a bachelor of science degree in microbiology from Purdue University and degree in immunology from the University of Texas, Southwestern Medical Center. Dr. Hedley currently serves as a director of Youville Place, Inc. She also served on the board of Receptos, Inc. prior to its acquisition by Celgene Corp. in August 2015.
James O. Armitage

James O. Armitage。自2013年5月,Armitage博士在我们的董事会任职。自2003年起,他一直是内布拉斯加大学医学中心(University of Nebraska Medical Center)内科血液学和肿瘤学的教授。自1982年加盟该中心他曾担任内科主任,药学院院长,以及其他各种职务,他还持有内布拉斯加医疗中心(The Nebraska Medical Center)和大学医院(University Hospital)的任命。Armitage博士撰写或合作撰写了超过545篇论文,100篇书刊篇章和编辑或合编教材27本。他曾担任 American Society of Clinical Oncology "ASCO" 的总裁和ASCO董事会成员。Armitage博士获内布拉斯加大学(University of Nebraska)理学学士学位和内布拉斯加大学医学中心(the University of Nebraska Medical Center)医学学位,并完成了他在内布拉斯加大学医学中心(University of Nebraska Medical Center)和爱荷华大学医院和诊所(the University of Iowa Hospitals and Clinics)的研究生培养。


James O. Armitage has served on our board of directors since May 2013. Dr. Armitage has been a professor of internal medicine in the division of hematology and oncology at the University of Nebraska Medical Center since 2003 after having served as chairman of the department of internal medicine, dean of the college of medicine, and in various other capacities since joining the Center in 1982. He also holds hospital appointments at The Nebraska Medical Center and University Hospital. Dr. Armitage has authored or co-authored more than 562 articles, 108 book chapters and edited or co-edited 27 textbooks. He has previously served as president of the American Society of Clinical Oncology ""ASCO"", and as a member of the ASCO board of directors. Dr. Armitage received a bachelor of science degree from the University of Nebraska and a medical degree from the University of Nebraska Medical Center and completed his post-graduate training at the University of Nebraska Medical Center and the University of Iowa Hospitals and Clinics.
James O. Armitage。自2013年5月,Armitage博士在我们的董事会任职。自2003年起,他一直是内布拉斯加大学医学中心(University of Nebraska Medical Center)内科血液学和肿瘤学的教授。自1982年加盟该中心他曾担任内科主任,药学院院长,以及其他各种职务,他还持有内布拉斯加医疗中心(The Nebraska Medical Center)和大学医院(University Hospital)的任命。Armitage博士撰写或合作撰写了超过545篇论文,100篇书刊篇章和编辑或合编教材27本。他曾担任 American Society of Clinical Oncology "ASCO" 的总裁和ASCO董事会成员。Armitage博士获内布拉斯加大学(University of Nebraska)理学学士学位和内布拉斯加大学医学中心(the University of Nebraska Medical Center)医学学位,并完成了他在内布拉斯加大学医学中心(University of Nebraska Medical Center)和爱荷华大学医院和诊所(the University of Iowa Hospitals and Clinics)的研究生培养。
James O. Armitage has served on our board of directors since May 2013. Dr. Armitage has been a professor of internal medicine in the division of hematology and oncology at the University of Nebraska Medical Center since 2003 after having served as chairman of the department of internal medicine, dean of the college of medicine, and in various other capacities since joining the Center in 1982. He also holds hospital appointments at The Nebraska Medical Center and University Hospital. Dr. Armitage has authored or co-authored more than 562 articles, 108 book chapters and edited or co-edited 27 textbooks. He has previously served as president of the American Society of Clinical Oncology ""ASCO"", and as a member of the ASCO board of directors. Dr. Armitage received a bachelor of science degree from the University of Nebraska and a medical degree from the University of Nebraska Medical Center and completed his post-graduate training at the University of Nebraska Medical Center and the University of Iowa Hospitals and Clinics.

高管简历

中英对照 |  中文 |  英文
Jeffrey H. Hanke

Jeffrey H. Hanke, 他曾一直担任负责研究与开发的执行副总裁,以及首席科学官(2015年6月以来)。加入我们之前,他曾担任Boehringer Ingelheim, Inc.的高级研究副总裁、全球生物治疗药物主管,在那里他曾领导公司的美国研究活动,并管理生物治疗药物集团(2010年以来)。他此前曾担任AstraZeneca的癌症研究副总裁,也曾担任Pfizer公司的研发组织的一些职务,并不断被提拔。他拥有超过25年的生物制药的研发经验。他持有Baylor College of Medicine的免疫学和微生物学的博士学位,以及Fordham University的生物学硕士学位。他完成了the University of Texas Southwestern Medical School的博士后训练。


Jeffrey H. Hanke has served as Executive Vice President, Research and Development, and Chief Scientific Officer since June 2015. Prior to joining us, Dr. Hanke was Senior Vice President, Research, and Global Head of Biotherapeutics at Boehringer Ingelheim, Inc., where he led the company's U.S. research activities and managed the biotherapeutics group, since 2010. He previously served as Vice President of Cancer Research at AstraZeneca, and in several roles of increasing responsibility within the R&D organization at Pfizer. Dr. Hanke has more than twenty-five years of experience in biopharmaceutical research and development. Dr. Hanke received his Ph.D. in immunology and microbiology from Baylor College of Medicine and his M.S. in biology from Fordham University. He completed his post-doctoral training at the University of Texas Southwestern Medical School.
Jeffrey H. Hanke, 他曾一直担任负责研究与开发的执行副总裁,以及首席科学官(2015年6月以来)。加入我们之前,他曾担任Boehringer Ingelheim, Inc.的高级研究副总裁、全球生物治疗药物主管,在那里他曾领导公司的美国研究活动,并管理生物治疗药物集团(2010年以来)。他此前曾担任AstraZeneca的癌症研究副总裁,也曾担任Pfizer公司的研发组织的一些职务,并不断被提拔。他拥有超过25年的生物制药的研发经验。他持有Baylor College of Medicine的免疫学和微生物学的博士学位,以及Fordham University的生物学硕士学位。他完成了the University of Texas Southwestern Medical School的博士后训练。
Jeffrey H. Hanke has served as Executive Vice President, Research and Development, and Chief Scientific Officer since June 2015. Prior to joining us, Dr. Hanke was Senior Vice President, Research, and Global Head of Biotherapeutics at Boehringer Ingelheim, Inc., where he led the company's U.S. research activities and managed the biotherapeutics group, since 2010. He previously served as Vice President of Cancer Research at AstraZeneca, and in several roles of increasing responsibility within the R&D organization at Pfizer. Dr. Hanke has more than twenty-five years of experience in biopharmaceutical research and development. Dr. Hanke received his Ph.D. in immunology and microbiology from Baylor College of Medicine and his M.S. in biology from Fordham University. He completed his post-doctoral training at the University of Texas Southwestern Medical School.
Grant C. Bogle

Grant C. Bogle自2015年7月起担任高级副总裁兼首席商务官。在加入我们之前,Bogle先生是McKesson Specialty Health的制药和生物技术解决方案高级副总裁,他是高级管理团队的一员 ,并领导了信息学,健康经济学和结果研究,报销访问和安全服务,以及美国肿瘤临床研究业务部门,这些业务部门由大约1000名员工组成。加入我们之前,Bogle先生是McKesson8年的员工。在此之前,他是Millennium Pharmaceuticals的销售和营销高级副总裁,负责肿瘤学产品—VELCADE。在加入Millennium之前,Bogle先生在许多其他制药公司担任高级销售和营销职位。他持有Columbia University的工商管理硕士和Dartmouth College的经济学学士学位。


Grant C. Bogle has served as Senior Vice President and Chief Commercial Officer since July 2015. Prior to joining us, Mr. Bogle was Senior Vice President, Pharmaceutical and Biotech Solutions at McKesson Specialty Health, where he was part of the executive leadership team and led the informatics, health economics and outcomes research, reimbursement access and safety services, and U.S. Oncology Clinical Research business units. These business units were comprised of approximately 1000 employees. Mr. Bogle was an employee of McKesson for eight years prior to joining us. Previously, he was Senior Vice President of Sales and Marketing for Millennium Pharmaceuticals, where he was responsible for the oncology product, VELCADE. Prior to joining Millennium, Mr. Bogle held senior sales and marketing roles at numerous other pharmaceutical companies. He holds an M.B.A. from Columbia University and a B.A. in economics from Dartmouth College.
Grant C. Bogle自2015年7月起担任高级副总裁兼首席商务官。在加入我们之前,Bogle先生是McKesson Specialty Health的制药和生物技术解决方案高级副总裁,他是高级管理团队的一员 ,并领导了信息学,健康经济学和结果研究,报销访问和安全服务,以及美国肿瘤临床研究业务部门,这些业务部门由大约1000名员工组成。加入我们之前,Bogle先生是McKesson8年的员工。在此之前,他是Millennium Pharmaceuticals的销售和营销高级副总裁,负责肿瘤学产品—VELCADE。在加入Millennium之前,Bogle先生在许多其他制药公司担任高级销售和营销职位。他持有Columbia University的工商管理硕士和Dartmouth College的经济学学士学位。
Grant C. Bogle has served as Senior Vice President and Chief Commercial Officer since July 2015. Prior to joining us, Mr. Bogle was Senior Vice President, Pharmaceutical and Biotech Solutions at McKesson Specialty Health, where he was part of the executive leadership team and led the informatics, health economics and outcomes research, reimbursement access and safety services, and U.S. Oncology Clinical Research business units. These business units were comprised of approximately 1000 employees. Mr. Bogle was an employee of McKesson for eight years prior to joining us. Previously, he was Senior Vice President of Sales and Marketing for Millennium Pharmaceuticals, where he was responsible for the oncology product, VELCADE. Prior to joining Millennium, Mr. Bogle held senior sales and marketing roles at numerous other pharmaceutical companies. He holds an M.B.A. from Columbia University and a B.A. in economics from Dartmouth College.
Martin H. Huber

Martin H. Huber,2015年9月以来,他一直担任我们的高级副总裁兼首席医疗官。加入公司之前(始于2009年),他曾担任Merck Research Laboratories的副总裁,负责肿瘤临床研究。他在生物制药行业有着超过20年的领导经验。任职Merck公司之前,他曾担任Schering-Plough, Hoffmann-La Roche和Rhone-Poulenc Rorer的多种职务,并不断被提拔,在那里他领导肿瘤学临床开发、药物安全性和药物警戒领域的团队。他此前曾担任the University of Texas MD Anderson Cancer Center的肿瘤学助理教授。他持有Baylor College of Medicine的医学博士学位。


Martin H. Huber has served as Senior Vice President and Chief Medical Officer since September 2015. Prior to joining the Company, beginning in 2009 Dr. Huber served as Vice President, Oncology Clinical Research, at Merck Research Laboratories. Dr. Huber has over 20 years of leadership experience in the biopharmaceutical industry. Prior to Merck, he served in roles of increasing responsibility at Schering-Plough, Hoffmann-La Roche and Rhone-Poulenc Rorer, where he led teams in the areas of oncology clinical development, drug safety and pharmacovigilance. He previously served as an assistant professor of oncology at the University of Texas MD Anderson Cancer Center. Dr. Huber received his M.D. from Baylor College of Medicine.
Martin H. Huber,2015年9月以来,他一直担任我们的高级副总裁兼首席医疗官。加入公司之前(始于2009年),他曾担任Merck Research Laboratories的副总裁,负责肿瘤临床研究。他在生物制药行业有着超过20年的领导经验。任职Merck公司之前,他曾担任Schering-Plough, Hoffmann-La Roche和Rhone-Poulenc Rorer的多种职务,并不断被提拔,在那里他领导肿瘤学临床开发、药物安全性和药物警戒领域的团队。他此前曾担任the University of Texas MD Anderson Cancer Center的肿瘤学助理教授。他持有Baylor College of Medicine的医学博士学位。
Martin H. Huber has served as Senior Vice President and Chief Medical Officer since September 2015. Prior to joining the Company, beginning in 2009 Dr. Huber served as Vice President, Oncology Clinical Research, at Merck Research Laboratories. Dr. Huber has over 20 years of leadership experience in the biopharmaceutical industry. Prior to Merck, he served in roles of increasing responsibility at Schering-Plough, Hoffmann-La Roche and Rhone-Poulenc Rorer, where he led teams in the areas of oncology clinical development, drug safety and pharmacovigilance. He previously served as an assistant professor of oncology at the University of Texas MD Anderson Cancer Center. Dr. Huber received his M.D. from Baylor College of Medicine.
Joseph L. Farmer

Joseph L. Farmer,2005年2月成为我们总法律顾问和法律事务副总裁。Farmer先生2008年5月晋升为法律事务高级副总裁,2011年12月成为首席行政官,自2007年他还曾担任我们的秘书长,在加入我们之前,从1997年到2005年Farmer先生是波士顿Testa, Hurwitz和Thibeault有限责任公司(Thibeault, LLP)律师事务所商务实践部的律师,Farmer先生目前担任波士顿管家卡尼医院(Steward Carney Hospital)托管理事会和病人护理咨询委员会成员。他获得波士顿大学(Boston University)经济学学士学位以及波士顿大学法学院(Boston College Law School)法学博士学位。


Joseph L. Farmer has served as Senior Vice President, General Counsel and Secretary since March 2015. From November 2012 until February 2015 Mr. Farmer served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharmaceuticals, Inc., prior to its sale to Merck & Co., Inc. Prior to joining Cubist, Mr. Farmer served as Vice President, General Counsel and Secretary of publicly-traded software company Pegasystems Inc. from June until November 2012. From February 2005 until June 2012 Mr. Farmer held management positions with increasing levels of responsibility at AMAG Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, including as its Chief Administrative Officer, General Counsel and Secretary. He received his B.A. in economics from Boston University and his J.D. from Boston College Law School.
Joseph L. Farmer,2005年2月成为我们总法律顾问和法律事务副总裁。Farmer先生2008年5月晋升为法律事务高级副总裁,2011年12月成为首席行政官,自2007年他还曾担任我们的秘书长,在加入我们之前,从1997年到2005年Farmer先生是波士顿Testa, Hurwitz和Thibeault有限责任公司(Thibeault, LLP)律师事务所商务实践部的律师,Farmer先生目前担任波士顿管家卡尼医院(Steward Carney Hospital)托管理事会和病人护理咨询委员会成员。他获得波士顿大学(Boston University)经济学学士学位以及波士顿大学法学院(Boston College Law School)法学博士学位。
Joseph L. Farmer has served as Senior Vice President, General Counsel and Secretary since March 2015. From November 2012 until February 2015 Mr. Farmer served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharmaceuticals, Inc., prior to its sale to Merck & Co., Inc. Prior to joining Cubist, Mr. Farmer served as Vice President, General Counsel and Secretary of publicly-traded software company Pegasystems Inc. from June until November 2012. From February 2005 until June 2012 Mr. Farmer held management positions with increasing levels of responsibility at AMAG Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, including as its Chief Administrative Officer, General Counsel and Secretary. He received his B.A. in economics from Boston University and his J.D. from Boston College Law School.
Mary Lynne Hedley

Mary Lynne Hedley自2010年3月共同创办公司担任公司总裁兼首席科学官,并是我们的董事会成员,从2009年7月至2010年2月Hedley博士担任Abraxis生物科学公司的运营部执行副总裁兼首席科学官,这是一家生物技术公司。从2008年1月至2009年7月Hedley博士担任北美卫材公司(Eisai Corporation of North America)的执行副总裁,该公司于2008年1月被MGI PHARMA公司收购。Hedley博士从2004年到2008年1月它收购Eisai,曾在MGI PHARMA不同的岗位任职,最近担任执行副总裁兼首席科学官。在此之前,Hedley博士于2004年共同创办Zycos,博士担任ZYCOS公司的总裁兼首席执行官,是一家生物技术公司,该公司被MGI制药公司收购。Hedley获得哈佛大学(Harvard University)两个连续的博士后奖学金。Hedley博士获得普渡大学(Purdue University)微生物学士学位和德克萨斯大学西南医学中心(the University of Texas, Southwestern Medical Center)免疫博士学位。


Mary Lynne Hedley has served as our President and as a member of our board of directors since co-founding the Company in March 2010. She also served in the role of Chief Scientific Officer from the Company's founding until the board of directors appointed her to the role of Chief Operating Officer effective July 24 2014. From July 2009 to February 2010 Dr. Hedley served as executive vice president of operations and chief scientific officer of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley served as executive vice president of Eisai Corporation of North America from January 2008 until July 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc. in January 2008. Dr. Hedley served in various positions at MGI PHARMA, Inc. from 2004 through its acquisition in January 2008 most recently as executive vice president and chief scientific officer. Prior to that, Dr. Hedley co-founded and served as the president and chief executive officer of ZYCOS, Inc., a biotechnology company, which was acquired by MGI PHARMA, Inc. in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University. Dr. Hedley earned a bachelor of science degree in microbiology from Purdue University and degree in immunology from the University of Texas, Southwestern Medical Center. Dr. Hedley currently serves as a director of Youville Place, Inc. She also served on the board of Receptos, Inc. prior to its acquisition by Celgene Corp. in August 2015.
Mary Lynne Hedley自2010年3月共同创办公司担任公司总裁兼首席科学官,并是我们的董事会成员,从2009年7月至2010年2月Hedley博士担任Abraxis生物科学公司的运营部执行副总裁兼首席科学官,这是一家生物技术公司。从2008年1月至2009年7月Hedley博士担任北美卫材公司(Eisai Corporation of North America)的执行副总裁,该公司于2008年1月被MGI PHARMA公司收购。Hedley博士从2004年到2008年1月它收购Eisai,曾在MGI PHARMA不同的岗位任职,最近担任执行副总裁兼首席科学官。在此之前,Hedley博士于2004年共同创办Zycos,博士担任ZYCOS公司的总裁兼首席执行官,是一家生物技术公司,该公司被MGI制药公司收购。Hedley获得哈佛大学(Harvard University)两个连续的博士后奖学金。Hedley博士获得普渡大学(Purdue University)微生物学士学位和德克萨斯大学西南医学中心(the University of Texas, Southwestern Medical Center)免疫博士学位。
Mary Lynne Hedley has served as our President and as a member of our board of directors since co-founding the Company in March 2010. She also served in the role of Chief Scientific Officer from the Company's founding until the board of directors appointed her to the role of Chief Operating Officer effective July 24 2014. From July 2009 to February 2010 Dr. Hedley served as executive vice president of operations and chief scientific officer of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley served as executive vice president of Eisai Corporation of North America from January 2008 until July 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc. in January 2008. Dr. Hedley served in various positions at MGI PHARMA, Inc. from 2004 through its acquisition in January 2008 most recently as executive vice president and chief scientific officer. Prior to that, Dr. Hedley co-founded and served as the president and chief executive officer of ZYCOS, Inc., a biotechnology company, which was acquired by MGI PHARMA, Inc. in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University. Dr. Hedley earned a bachelor of science degree in microbiology from Purdue University and degree in immunology from the University of Texas, Southwestern Medical Center. Dr. Hedley currently serves as a director of Youville Place, Inc. She also served on the board of Receptos, Inc. prior to its acquisition by Celgene Corp. in August 2015.